



PRESS RELEASE - September 17, 2025 – 2:00pm CEST - Montpellier, France - Euronext: MEDCL

## Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

---

Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California

Teva will host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 am ET to discuss these data

To access a live webcast of the presentation, visit Teva's Investor Relations website at <https://ir.tevapharm.com/Events-and-Presentations>

---

Olanzapine LAI (mdc-TJK / TEV-'749) is an investigational, once-monthly, subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. This is the second drug within the Teva partnership – after UZEDY® approved by the FDA in April 2023 – that uses Medincell's co-polymer technology (licensed to Teva under the name SteadyTeq™) to generate a controlled steady release of drug throughout the dosing interval. Teva is currently preparing for regulatory submission and launch of Olanzapine LAI with NDA submission anticipated in Q4 2025.

### About Medincell

---

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.

These treatments combine active pharmaceutical ingredients with our proprietary BEPO® technology, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.

The first treatment based on BEPO® technology was approved for schizophrenia by the FDA in April 2023 and is now marketed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™)

Our investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.

Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.

**medincell.com**

*UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals.*

### Contact

---

**David Heuzé**

Head of Corporate and Financial Communications, and ESG  
[david.heuze@Medincell.com](mailto:david.heuze@Medincell.com) / +33 (0)6 83 25 21 86

**Grace Kim**

Chief Strategy Officer, U.S. Finance  
[grace.kim@medincell.com](mailto:grace.kim@medincell.com) / +1 (646) 991-4023

**Nicolas Mérieau / Arthur Rouillé**

Media Relations  
[Medincell@newcap.eu](mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94

**Louis-Victor Delouvrier / Alban Dufumier**

Investor Relations France  
[Medincell@newcap.eu](mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94

This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities.

These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements.

A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements.

This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.